We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cempra's Application for Pneumonia Drug Validated in EU
Read MoreHide Full Article
Cempra, Inc. announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia (CABP).
CABP is commonly known as community-acquired pneumonia (CAP) in the EU. As per the information provided by the company, upon approval, solithromycin would be the first new oral and IV antibiotic available in the EU in more than 15 years. According to the European Respiratory Society (ERS), more than 3,000,000 cases of CAP are diagnosed annually, resulting in approximately 1,000,000 hospitalizations.
Since the EMA has validated the application, the submission is deemed to be complete and the formal review process will start shortly. The EMA’s Committee for Medicinal Products for Human Use (CHMP) will start the assessment of solithromycin under a centralized review procedure followed by the European Commission.
A potential approval and successful commercialization will significantly boost Cempra’s growth prospects as the company does not have any approved product in its portfolio yet. It is developing solithromycin in oral capsules, IV and suspension formulations. Solithera (solithromycin) is one of the two lead product candidates at Cempra.
The company also has a new drug application for solithromycin for the treatment of CABP under review in the U.S. Meanwhile, the company is evaluating solithromycin is in a phase III study for the treatment of uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia.
We note that Allergan’s Teflaro is also approved for the treatment of CABP.
Another candidate in Cempra’s pipeline is Taksta, which is being evaluated in a phase III study for the treatment of patients with acute bacterial skin and skin structure infections.
Cempra currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and Corcept Therapeutics Inc. (CORT - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cempra's Application for Pneumonia Drug Validated in EU
Cempra, Inc. announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia (CABP).
CABP is commonly known as community-acquired pneumonia (CAP) in the EU. As per the information provided by the company, upon approval, solithromycin would be the first new oral and IV antibiotic available in the EU in more than 15 years. According to the European Respiratory Society (ERS), more than 3,000,000 cases of CAP are diagnosed annually, resulting in approximately 1,000,000 hospitalizations.
Since the EMA has validated the application, the submission is deemed to be complete and the formal review process will start shortly. The EMA’s Committee for Medicinal Products for Human Use (CHMP) will start the assessment of solithromycin under a centralized review procedure followed by the European Commission.
CEMPRA INC Price
CEMPRA INC Price | CEMPRA INC Quote
A potential approval and successful commercialization will significantly boost Cempra’s growth prospects as the company does not have any approved product in its portfolio yet. It is developing solithromycin in oral capsules, IV and suspension formulations. Solithera (solithromycin) is one of the two lead product candidates at Cempra.
The company also has a new drug application for solithromycin for the treatment of CABP under review in the U.S. Meanwhile, the company is evaluating solithromycin is in a phase III study for the treatment of uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia.
We note that Allergan’s Teflaro is also approved for the treatment of CABP.
Another candidate in Cempra’s pipeline is Taksta, which is being evaluated in a phase III study for the treatment of patients with acute bacterial skin and skin structure infections.
Cempra currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and Corcept Therapeutics Inc. (CORT - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>